皮肤癌管理——默克尔细胞癌的最新进展
Skin cancer management-updates on Merkel cell carcinoma.
作者信息
Tai Patricia, Au Joseph
机构信息
Allan Blair Cancer Center, University of Saskatchewan, Saskatoon, Canada.
Adventist Hospital, University of Hong Kong, Hong Kong, China.
出版信息
Ann Transl Med. 2018 Jul;6(14):282. doi: 10.21037/atm.2018.06.13.
Abstract
There are many different types of skin tumors in the World Health Organization (WHO) classification. The natural course and treatment varies according to the histological type. This review summarizes clinical experience for treatment decision. Contemporary radiotherapy and systemic therapy are improving. Landmark studies for basal cell and Merkel cell carcinomas (MCC) trigger further research and impetus for improving treatment outcome. Avelumab, nivolumab, pembrolizumab, ipilimumab appear to be promising for treatment of advanced MCCs and adjuvant trials are underway.
摘要
世界卫生组织（WHO）分类中有许多不同类型的皮肤肿瘤。其自然病程和治疗方法因组织学类型而异。本综述总结了治疗决策的临床经验。当代放疗和全身治疗正在不断改进。基底细胞癌和默克尔细胞癌（MCC）的标志性研究引发了进一步的研究，并推动了改善治疗结果的动力。阿维鲁单抗、纳武单抗、帕博利珠单抗、伊匹木单抗在晚期MCC的治疗中似乎很有前景，辅助试验正在进行中。
相似文献
1
Skin cancer management-updates on Merkel cell carcinoma.皮肤癌管理——默克尔细胞癌的最新进展
Ann Transl Med. 2018 Jul;6(14):282. doi: 10.21037/atm.2018.06.13.
2
Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.最近默克尔细胞癌患者的治疗进展和治疗模式的改变。
Oncologist. 2019 Oct;24(10):1375-1383. doi: 10.1634/theoncologist.2018-0718. Epub 2019 Apr 8.
3
Immunotherapy for Merkel Cell Carcinoma.默克尔细胞癌的免疫治疗。
Curr Treat Options Oncol. 2018 Sep 20;19(11):57. doi: 10.1007/s11864-018-0574-5.
4
Merkel Cell Carcinoma Therapeutic Update.默克尔细胞癌的治疗进展
Curr Treat Options Oncol. 2016 Jul;17(7):36. doi: 10.1007/s11864-016-0409-1.
5
Avelumab: a new standard for treating metastatic Merkel cell carcinoma.阿维鲁单抗：治疗转移性 Merkel 细胞癌的新标准。
Expert Rev Anticancer Ther. 2018 Apr;18(4):319-326. doi: 10.1080/14737140.2018.1445528. Epub 2018 Feb 28.
6
Avelumab and other recent advances in Merkel cell carcinoma.阿维鲁单抗和 Merkel 细胞癌的其他最新进展。
Future Oncol. 2017 Dec;13(30):2771-2783. doi: 10.2217/fon-2017-0305. Epub 2017 Oct 4.
7
Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy.默克尔细胞癌：流行病学、发病机制、诊断与治疗。
Rev Endocr Metab Disord. 2017 Dec;18(4):517-532. doi: 10.1007/s11154-017-9433-0.
8
Epidemiological, Clinicopathological and Virological Features of Merkel Cell Carcinomas in Medical Center of University of Pécs, Hungary (2007-2012).匈牙利佩奇大学医学中心默克尔细胞癌的流行病学、临床病理及病毒学特征（2007 - 2012年）
Pathol Oncol Res. 2016 Jan;22(1):71-7. doi: 10.1007/s12253-015-9974-z. Epub 2015 Aug 26.
9
[Personalized medicine in the treatment of periocular tumors : Targeted treatment and use of immune checkpoint inhibitors].[个性化医疗在眼周肿瘤治疗中的应用：靶向治疗与免疫检查点抑制剂的使用]
Ophthalmologe. 2020 Jun;117(6):521-527. doi: 10.1007/s00347-019-01034-z.
10
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.MCPyV阳性和MCPyV阴性默克尔细胞癌的突变图谱及其对免疫治疗的意义。
Oncotarget. 2016 Jan 19;7(3):3403-15. doi: 10.18632/oncotarget.6494.
引用本文的文献
1
Merkel Cell Carcinoma of the Skin: Deducing the Pattern of Spread from an International Aggregated Database of 949 Patients.皮肤默克尔细胞癌：从949例患者的国际汇总数据库推导其扩散模式
Curr Oncol. 2025 Apr 2;32(4):211. doi: 10.3390/curroncol32040211.
2
Merkel-Cell Carcinoma: Local Recurrence Rate Versus Radiation Dose Study from a 949-Patient Database.默克尔细胞癌：来自949例患者数据库的局部复发率与放射剂量研究
Curr Oncol. 2025 Mar 28;32(4):202. doi: 10.3390/curroncol32040202.
3
Best practices in surgical and nonsurgical management of head and neck Merkel cell carcinoma: An update.头颈部 Merkel 细胞癌手术和非手术治疗的最佳实践：更新。
Mol Carcinog. 2023 Jan;62(1):101-112. doi: 10.1002/mc.23483. Epub 2022 Nov 11.
4
Outcome of early stage Merkel carcinoma treated by exclusive radiation: a study of 53 patients.早期 Merkel 细胞癌单纯放疗的疗效：53 例患者研究。
Radiat Oncol. 2021 May 14;16(1):90. doi: 10.1186/s13014-021-01815-4.
本文引用的文献
1
Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience.晚期基底细胞癌进展后维莫德吉再治疗：单机构经验的首次报告。
Target Oncol. 2018 Apr;13(2):253-256. doi: 10.1007/s11523-017-0545-y.
2
Research gaps in the management and prevention of cutaneous squamous cell carcinoma in organ transplant recipients.器官移植受者皮肤鳞状细胞癌的管理和预防中的研究空白。
Br J Dermatol. 2017 Nov;177(5):1225-1233. doi: 10.1111/bjd.15950. Epub 2017 Oct 30.
3
New era of electronic brachytherapy.电子近距离放射治疗的新时代。
World J Radiol. 2017 Apr 28;9(4):148-154. doi: 10.4329/wjr.v9.i4.148.
4
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial.两种间断维莫德吉给药方案治疗多发性基底细胞癌患者（MIKIE）：一项随机、方案对照、双盲、2 期试验。
Lancet Oncol. 2017 Mar;18(3):404-412. doi: 10.1016/S1470-2045(17)30072-4. Epub 2017 Feb 8.
5
More than skin deep? Potential nicotinamide treatment applications in chronic kidney transplant recipients.不止于表面？烟酰胺在慢性肾移植受者中的潜在治疗应用。
World J Transplant. 2016 Dec 24;6(4):658-664. doi: 10.5500/wjt.v6.i4.658.
6
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.阿维鲁单抗治疗化疗难治性转移性默克尔细胞癌患者：一项多中心、单组、开放标签的2期试验。
Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.
7
1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis.1-甲基烟酰胺及其结构类似物1,4-二甲基吡啶用于预防癌症转移。
J Exp Clin Cancer Res. 2016 Jul 13;35(1):110. doi: 10.1186/s13046-016-0389-9.
8
Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma.维莫德吉治疗基底细胞癌后皮肤鳞状细胞癌风险增加。
JAMA Dermatol. 2016 May 1;152(5):527-32. doi: 10.1001/jamadermatol.2015.4330.
9
Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.基底细胞痣综合征的间歇性维莫德吉治疗
JAMA Dermatol. 2016 Feb;152(2):223-4. doi: 10.1001/jamadermatol.2015.3210.
10
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.一项烟酰胺用于皮肤癌化学预防的 3 期随机试验。
N Engl J Med. 2015 Oct 22;373(17):1618-26. doi: 10.1056/NEJMoa1506197.
Zotero 插件